Alpha Tau Medical (DRTS) Expected to Announce Quarterly Earnings on Tuesday

Alpha Tau Medical (NASDAQ:DRTS) is projected to release its Q3 2025 results before the market opens on Tuesday, November 18th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 18, 2025 at 12:00 AM ET.

Alpha Tau Medical Stock Down 4.1%

Shares of DRTS stock opened at $3.71 on Friday. The company has a market capitalization of $314.68 million, a price-to-earnings ratio of -7.73 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.81 and a current ratio of 10.52. Alpha Tau Medical has a twelve month low of $2.20 and a twelve month high of $4.69. The stock’s 50 day simple moving average is $4.01 and its 200 day simple moving average is $3.40.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Alpha Tau Medical to a “sell” rating in a report on Saturday, November 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.00.

Institutional Trading of Alpha Tau Medical

A hedge fund recently bought a new stake in Alpha Tau Medical stock. Envestnet Asset Management Inc. acquired a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 13,765 shares of the company’s stock, valued at approximately $62,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.